These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 8873503)

  • 1. Biochemical and radiologic improvement in Paget's disease of bone treated with alendronate: a randomized, placebo-controlled trial.
    Reid IR; Nicholson GC; Weinstein RS; Hosking DJ; Cundy T; Kotowicz MA; Murphy WA; Yeap S; Dufresne S; Lombardi A; Musliner TA; Thompson DE; Yates AJ
    Am J Med; 1996 Oct; 101(4):341-8. PubMed ID: 8873503
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative study of alendronate versus etidronate for the treatment of Paget's disease of bone.
    Siris E; Weinstein RS; Altman R; Conte JM; Favus M; Lombardi A; Lyles K; McIlwain H; Murphy WA; Reda C; Rude R; Seton M; Tiegs R; Thompson D; Tucci JR; Yates AJ; Zimering M
    J Clin Endocrinol Metab; 1996 Mar; 81(3):961-7. PubMed ID: 8772558
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized clinical trial comparing oral alendronate and intravenous pamidronate for the treatment of Paget's disease of bone.
    Walsh JP; Ward LC; Stewart GO; Will RK; Criddle RA; Prince RL; Stuckey BG; Dhaliwal SS; Bhagat CI; Retallack RW; Kent GN; Drury PJ; Vasikaran S; Gutteridge DH
    Bone; 2004 Apr; 34(4):747-54. PubMed ID: 15050907
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alendronate in the treatment of Paget's disease of bone.
    Khan SA; Vasikaran S; McCloskey EV; Benéton MN; Rogers S; Coulton L; Orgee J; Coombes G; Kanis JA
    Bone; 1997 Mar; 20(3):263-71. PubMed ID: 9071478
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of Paget's disease of bone with alendronate.
    Lombardi A
    Bone; 1999 May; 24(5 Suppl):59S-61S. PubMed ID: 10321931
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alendronate in the treatment of Paget's disease of bone.
    Reid IR; Siris E
    Int J Clin Pract Suppl; 1999 Apr; 101():62-6. PubMed ID: 12669742
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Measurement of urinary excretion of nonisomerized and beta-isomerized forms of type I collagen breakdown products to monitor the effects of the bisphosphonate zoledronate in Paget's disease.
    Garnero P; Gineyts E; Schaffer AV; Seaman J; Delmas PD
    Arthritis Rheum; 1998 Feb; 41(2):354-60. PubMed ID: 9485094
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low dose of oral alendronate decreases bone turnover in Japanese patients with Paget's disease of bone.
    Takada J; Iba K; Yamashita T
    J Bone Miner Metab; 2005; 23(4):333-6. PubMed ID: 15981032
    [No Abstract]   [Full Text] [Related]  

  • 9. Risedronate: a new oral bisphosphonate.
    Umland EM; Boyce EG
    Clin Ther; 2001 Sep; 23(9):1409-21. PubMed ID: 11589256
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized, active-controlled study of once-weekly alendronate 280 mg high dose oral buffered solution for treatment of Paget's disease.
    Hooper M; Faustino A; Reid IR; Hosking D; Gilchrist NL; Selby P; Wu M; Salzmann G; West J; Leung A
    Osteoporos Int; 2009 Jan; 20(1):141-50. PubMed ID: 18536953
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of five daily 1 h infusions of alendronate in Paget's disease of bone.
    O'Doherty DP; Gertz BJ; Tindale W; Sciberras DG; Survill TT; Kanis JA
    J Bone Miner Res; 1992 Jan; 7(1):81-7. PubMed ID: 1549961
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic strategy in Paget's disease of bone.
    Meunier PJ; Vignot E
    Bone; 1995 Nov; 17(5 Suppl):489S-491S. PubMed ID: 8573424
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alendronate in primary hyperparathyroidism: a double-blind, randomized, placebo-controlled trial.
    Khan AA; Bilezikian JP; Kung AW; Ahmed MM; Dubois SJ; Ho AY; Schussheim D; Rubin MR; Shaikh AM; Silverberg SJ; Standish TI; Syed Z; Syed ZA
    J Clin Endocrinol Metab; 2004 Jul; 89(7):3319-25. PubMed ID: 15240609
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Additional beneficial effects of alendronate in growth hormone (GH)-deficient adults with osteoporosis receiving long-term recombinant human GH replacement therapy: a randomized controlled trial.
    Biermasz NR; Hamdy NA; Janssen YJ; Roelfsema F
    J Clin Endocrinol Metab; 2001 Jul; 86(7):3079-85. PubMed ID: 11443170
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship between biochemical markers of bone turnover and bone scintigraphic indices in assessment of Paget's disease activity.
    Alvarez L; Peris P; Pons F; Guañabens N; Herranz R; Monegal A; Bedini JL; Deulofeu R; Martínez de Osaba MJ; Muñoz-Gómez J; Ballesta AM
    Arthritis Rheum; 1997 Mar; 40(3):461-8. PubMed ID: 9082934
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Usefulness of biochemical markers of bone turnover in assessing response to the treatment of Paget's disease.
    Alvarez L; Guañabens N; Peris P; Vidal S; Ros I; Monegal A; Bedini JL; Deulofeu R; Pons F; Muñoz-Gomez J; Ballesta AM
    Bone; 2001 Nov; 29(5):447-52. PubMed ID: 11704497
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantitative evaluation of bone scintigraphy in the assessment of Paget's disease activity.
    Pons F; Alvarez L; Peris P; Guañabens N; Vidal-Sicart S; Monegal A; Pavía J; Ballesta AM; Muños-Gómez J; Herranz R
    Nucl Med Commun; 1999 Jun; 20(6):525-8. PubMed ID: 10451864
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The bisphosphonate zoledronate decreases type II collagen breakdown in patients with Paget's disease of bone.
    Garnero P; Christgau S; Delmas PD
    Bone; 2001 May; 28(5):461-4. PubMed ID: 11344044
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: a randomized clinical trial.
    Greenspan SL; Parker RA; Ferguson L; Rosen HN; Maitland-Ramsey L; Karpf DB
    J Bone Miner Res; 1998 Sep; 13(9):1431-8. PubMed ID: 9738515
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Duration of the effects of intravenous alendronate in postmenopausal women and in patients with primary hyperparathyroidism and Paget's disease of bone.
    Adami S; Zamberlan N; Mian M; Dorizzi R; Rossini M; Braga B; Gatti D; Bertoldo F; Locascio V
    Bone Miner; 1994 May; 25(2):75-82. PubMed ID: 8086853
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.